Haag-Streit Appoints Thomas Lenzen as New CEO

Haag-Streit announced the appointment of Thomas Lenzen as Chief Executive Officer of the Haag-Streit Group, effective September 1, 2025.

According to Haag-Streit, with more than two decades of international leadership experience in the med tech industry, Mr. Lenzen brings deep expertise in ophthalmology and a proven track record of driving business growth. He previously held senior leadership roles at Bausch + Lomb, where he led the Business Unit Surgical for DACH, and later served as general manager for the DACH region. Most recently, he was Vice President International at Haemonetics, overseeing the company’s international operations for the business unit plasma and blood center.

“Haag-Streit has a remarkable history of shaping ophthalmology through pioneering solutions and a strong commitment to precision and quality. I am honored to lead the company into its next phase of growth," said Mr. Lenzen. "Together with my new colleagues around the world, I look forward to building on the strength of the current portfolio and driving our strategy forward with energy, innovation, and passion.”

Mr. Lenzen succeeds Thomas Bernhard, who led Haag-Streit as CEO since 2021. 

“It has been a privilege to serve Haag-Streit for more than a decade, and I am proud of what we have achieved together as “One Haag-Streit,” Mr. Bernhard said. "Our groundbreaking innovations, including the Eyestar 900, METIS 900, Elara 900, and Refractor 900, alongside the transformation of individual companies into a cohesive and strategically unified organization, have laid a powerful foundation for future growth. I warmly welcome Thomas Lenzen as my successor and wish him every success in this exciting role.”